The Milvexian back story is curious. JNJ, who partnered with Bayer on Xarelto in the oral-FXa market, chose to partner with BMY on Milvexian in the FXIa market rather than partnering with Bayer on Asundexian.
Xarelto was a big-selling drug, but not nearly as big as BMY’s Eliquis. I wonder if JNJ thinks it was outmaneuvered in the FXa market and became determined not to let it happen again with FXIa.
Meanwhile, PFE, who partnered with BMY on Eliquis, is not pursuing FXIa.
News 
Market Data 
Discover 
